"Drugs, Investigational" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs which have received FDA approval for human testing but have yet to be approved for commercial marketing. This includes drugs used for treatment while they still are undergoing clinical trials (Treatment IND). The main heading includes drugs under investigation in foreign countries.
| Descriptor ID |
D015507
|
| MeSH Number(s) |
D26.371
|
| Concept/Terms |
Drugs, Investigational- Drugs, Investigational
- Investigational New Drugs
- Drugs, Investigational New
- New Drugs, Investigational
- Investigational Drugs
|
Below are MeSH descriptors whose meaning is more general than "Drugs, Investigational".
Below are MeSH descriptors whose meaning is more specific than "Drugs, Investigational".
This graph shows the total number of publications written about "Drugs, Investigational" by people in this website by year, and whether "Drugs, Investigational" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drugs, Investigational" by people in Profiles.
-
Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials. Lancet. 2022 08 13; 400(10351):512-521.
-
Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease. N Engl J Med. 2019 10 24; 381(17):1644-1652.
-
Experimental therapies: Investigator-initiated cancer trials with INDs for approval in Japan. Nat Rev Clin Oncol. 2010 Mar; 7(3):127-8.
-
Emergence of targeted immune therapies for systemic lupus. Expert Opin Emerg Drugs. 2005 Feb; 10(1):53-65.
-
Challenges in bringing the bench to bedside in drug development for SLE. Nat Rev Drug Discov. 2004 Dec; 3(12):1036-46.
-
Dehydroepiandrosterone, a sex steroid metabolite in development for systemic lupus erythematosus. Expert Opin Investig Drugs. 2003 Jun; 12(6):1017-25.